Prior therapies as prognostic factors of overall survival in metastatic castration-resistant prostate cancer patients treated with [177Lu] Lu-PSMA-617. A WARMTH multicenter study (the 617 trial)
15 Feb 2021Please read abstract in the article.
| Authors: | Ahmadzadehfar, Hojjat, Rahbar, Kambiz, Baum, Richard P., Seifert, Robert, Kessel, Katharina, Bogemann, Martin, Kulkarni, Harshad R., Zhang, Jingjing, Gerke, Carolin, Fimmers, Rolf, Kratochwil, Clemens, Rathke, Hendrik, Ilhan, Harun, Maffey-Steffan, Johanna, Sathekge, Mike Machaba, Kabasakal, Levent, Osvaldo Garcia-Perez, Francisco, Kairemo, Kalevi, Maharaj, Masha, Paez, Diana, Virgolini, Irene |
| Institution: | University of Pretoria |
| Keywords: | Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC), Radioligand therapy, Lu-PSMA, Chemotherapy, Castration-resistant prostate cancer (CRPC), Metastatic CRPC (mCRPC) |